Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1

Zev Sthoeger, Amir Sharabi, Heidy Zinger, Ilan Asher, Edna Mozes

Research output: Contribution to journalArticlepeer-review

Abstract

וֹndoleamine-2,3-dioxygenase (IDO) plays a role in immune regulation. Increased IDO activity was reported in systemic lupus erythematosus (SLE). We investigated the effects of the tolerogenic peptide hCDR1, shown to ameliorate lupus manifestations, on IDO gene expression. mRNA was prepared from splenocytes of hCDR1- treated SLE-afflicted (NZBxNZW)F1 mice, from blood samples of lupus patients, collected before and after their in vivo treatment with hCDR1 and from peripheral blood mononuclear cells (PBMC) of patients incubated with hCDR1. IDO gene expression was determined by real-time RT-PCR. hCDR1 significantly down-regulated IDO expression in SLE-affected mice and in lupus patients (treated in vivo and in vitro). No effects were observed in healthy donors or following treatment with a control peptide. Diminished IDO gene expression was associated with hCDR1 beneficial effects. Our results suggest that the hCDR1-induced FOXP3 expressing regulatory T cells in lupus are not driven by IDO but rather by other hCDR1 regulated pathways.

Original languageEnglish
Pages (from-to)34-39
Number of pages6
JournalClinical Immunology
Volume197
DOIs
StatePublished - Dec 2018
Externally publishedYes

Keywords

  • Cytokines
  • FOXP3
  • Immunomodulation of gene expression
  • Indoleamine 2,3-dioxygenase (IDO)
  • Systemic lupus erythematosus (SLE)
  • Tolerogenic peptide (hCDR1)

Fingerprint

Dive into the research topics of 'Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1'. Together they form a unique fingerprint.

Cite this